Weiss Asset Management LP Invests $3.62 Million in Amgen Inc. (NASDAQ:AMGN)

Weiss Asset Management LP purchased a new position in Amgen Inc. (NASDAQ:AMGN – Get Rating) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,050 shares of the medical research company’s stock, valued at approximately $3,618,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Amgen by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 47,459,511 shares of the medical research company’s stock worth $10,697,373,000 after purchasing an additional 1,310,894 shares in the last quarter. FMR LLC boosted its stake in Amgen by 24.9% during the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock worth $2,168,140,000 after buying an additional 1,774,223 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Amgen by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after buying an additional 94,565 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Amgen by 1.3% during the 3rd quarter. Royal Bank of Canada now owns 6,097,683 shares of the medical research company’s stock worth $1,374,419,000 after acquiring an additional 75,721 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Amgen by 1.6% during the 3rd quarter. California Public Employees Retirement System now owns 2,462,101 shares of the medical research company’s stock valued at $554,958,000 after acquiring an additional 37,706 shares during the last quarter. 75.53% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 2.0 %

Shares of AMGN stock opened at $229.79 on Friday. Amgen Inc. has a fifty-two week low of $223.30 and a fifty-two week high of $296.67. The company has a 50 day moving average price of $245.91 and a 200 day moving average price of $254.81. The stock has a market capitalization of $122.70 billion, a P/E ratio of 18.98, a price-to-earnings-growth ratio of 1.89 and a beta of 0.65. The company has a debt-to-equity ratio of 10.20, a quick ratio of 1.10 and a current ratio of 1.41.

Amgen (NASDAQ:AMGN – Get Rating) last posted its quarterly earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, topping the consensus estimate of $4.04 by $0.05. The business had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.36 earnings per share. Equities research analysts predict that Amgen Inc. will post 17.72 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be given a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date is Wednesday, May 17th. Amgen’s dividend payout ratio is currently 70.36%.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMGN. Argus reduced their target price on shares of Amgen from $300.00 to $270.00 in a research note on Monday, February 6th. BMO Capital Markets decreased their price objective on Amgen from $276.00 to $253.00 and set a “market perform” rating on the stock in a report on Wednesday, February 1st. Credit Suisse Group cut their target price on Amgen from $240.00 to $220.00 and set an “underperform” rating for the company in a research note on Wednesday, February 1st. Cowen decreased their price target on Amgen from $307.00 to $289.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Finally, Piper Sandler cut their price objective on Amgen from $299.00 to $293.00 and set an “overweight” rating for the company in a research report on Thursday, January 19th. Four analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $251.44.

Amgen Company Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.